Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study

We aimed to assess the long-term safety and effectiveness of ocrelizumab in a cohort of patients with multiple sclerosis (MS) at high risk of progressive multifocal leukoencephalopathy (PML), previously treated with natalizumab in extending interval dosing (EID), who switched to ocrelizumab and to c...

Descripción completa

Detalles Bibliográficos
Autores principales: Santiago-Setien, Pilar, Barquín-Rego, Cristina, Hernández-Martínez, Paula, Ezquerra-Marigomez, María, Torres-Barquin, Marta, Menéndez-Garcia, Cristina, Uriarte, Fernando, Jiménez-López, Yésica, Misiego, Mercedes, Sánchez de la Torre, Jose Ramón, Setien, Sonia, Delgado-Alvarado, Manuel, Riancho, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929864/
https://www.ncbi.nlm.nih.gov/pubmed/36817456
http://dx.doi.org/10.3389/fimmu.2023.1086028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929864/
https://www.ncbi.nlm.nih.gov/pubmed/36817456
http://dx.doi.org/10.3389/fimmu.2023.1086028

Ejemplares similares